Prof. Dr. Nikolas Christian Cornelius von Bubnoff is a highly accomplished doctor specializing in internal medicine, hematology, and internal oncology. Dr. Bubnoff works at the Department of Hematology and Oncology at the University Hospital Schleswig-Holstein in Lubeck, Germany. He has received prestigious awards, including the Science Prize of the Gastrointestinal Stromal Tumors group in Switzerland, the Best of Hematology Award from the German Society for Hematology and Medical Oncology, and the Richtzenhain Prize for pioneering scientific work in the field of translational cancer research. He has also been recognized for his contributions to the medical community through his referee duties and editorial board memberships. Dr. Bubnoff's research and clinical practice are backed by an impressive publication record, with 222 scientific publications. His work focuses on guiding therapeutic decisions in patients with rare cancers and utilizing genomic analysis for personalized treatment. His expertise in liquid biopsy and the detection of rare mutations in cancers has significantly contributed to advancing cancer care.
Prof. Dr. Nikolas Christian Cornelius von Bubnoff is a highly accomplished doctor specializing in internal medicine, hematology, and internal oncology. Dr. Bubnoff works at the Department of Hematology and Oncology at the University Hospital Schleswig-Holstein in Lubeck, Germany. He has received prestigious awards, including the Science Prize of the Gastrointestinal Stromal Tumors group in Switzerland, the Best of Hematology Award from the German Society for Hematology and Medical Oncology, and the Richtzenhain Prize for pioneering scientific work in the field of translational cancer research. He has also been recognized for his contributions to the medical community through his referee duties and editorial board memberships. Dr. Bubnoff's research and clinical practice are backed by an impressive publication record, with 222 scientific publications. His work focuses on guiding therapeutic decisions in patients with rare cancers and utilizing genomic analysis for personalized treatment. His expertise in liquid biopsy and the detection of rare mutations in cancers has significantly contributed to advancing cancer care.